

6 March 2020

The Manager
ASX Announcements
Australian Securities Exchange
Level 4
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

ASX Appendix 3Y

The Company refers to the following public announcements:

- (a) On 3 March 2020, the Company confirmed the initiation of the pivotal study for soft tissue reconstruction with the enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, Arizona.
- (b) On 5 March 2020, the Company confirmed the initiation of a pivotal trial for the treatment of pediatric scald injuries with enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, Arizona.
- (c) The vesting of various restricted stock units for the Company's Chief Executive Officer, Dr Mike Perry, in connection with the achievement of the above corporate milestones (as confirmed by an ASX Appendix 2A released by the Company on each of the above dates).

Pursuant to the above, please find attached an ASX Appendix 3Y recording a change in Dr Perry's interests in the Company.

Please note that the disposal (i.e. sale) of shares by Dr Perry as reflected in the attached ASX Appendix 3Y are sales executed solely for the purposes of satisfying Dr Perry's income tax liability payable to the U.S. Internal Revenue Service and various State tax authorities (i.e. all sales are solely to cover income tax liability).

Authorized by

David McIntyre
Chief Financial Officer

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	AVITA Medical Limited
ABN	28 058 466 523

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	4 March 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	4 & 5 March 2020
No. of securities held prior to change	19,553,248 Ordinary Shares 46,592,658 Unlisted Restricted Stock Units, LTI Plan 15,000,000 Unlisted Options
Class	Ordinary Shares; and Unlisted Restricted Stock Units, LTI Plan (RSU's)
Number acquired	6,850,484 Ordinary Shares
Number disposed	6,434,219 Ordinary Shares; and 6,850,484 RSU's

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Acquisition of 6,850,484 ordinary shares - Nil consideration, issued as part of conversion of Director's RSU's Disposal of 3,258,044 shares - \$ 0.6248 per share Disposal of 3,176,175 shares - \$0.6169 per share
No. of securities held after change	19,969,513 Ordinary Shares 39,742,174 Unlisted Restricted Stock Units, LTI Plan 15,000,000 Unlisted Options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquisition - Conversion of Unlisted Restricted Stock Units, LTI Plan Disposal - On market sale

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.